Growth & Emerging Markets (GEM)

We Believe Every Person Everywhere Should Have Access to Medicine

The Growth & Emerging Markets (GEM) Business Unit (BU) is a core growth driver for Takeda globally. Our ambition is to drive profitable, sustainable growth by striving to address complex and rare diseases across GEM, which Takeda is uniquely placed to do. Our strong portfolio and pipeline of innovative medicines is aligned with the unmet needs of patients within GEM – a region characterized by diverse patient- and country-specific challenges.

By 2050, GEM will represent 85% of the total world population, adding around two billion people by that year. The countries and territories within GEM are highly dynamic, with burgeoning middle-class populations, growing healthcare budgets and rapidly rising demands for healthcare services and medicines.

The diversity of our regions, the complexity of the diseases we treat and our growth trajectory mean our employees have every opportunity to make an impact on patients’ lives and their careers.

Attracting & retaining top talent

宝石战略的一个关键部分是吸引和retain top talent with a diverse set of skills by providing a purposeful, inclusive and positive workplace for every Takeda employee. Our senior GEM leadership team is truly diverse, with its members representing 14 nationalities, and close to 50% are women.

Takeda has made great progress as part of a select group of only 13 companies globally to receive Global Top Employer status for the third year running in 2020, awarded by the Top Employer Institute, with 24 Takeda GEM country operations receiving external recognition.

Access to Medicines

Takeda is radically increasing access to innovative medicines for complex and rare diseases by mobilizing collective action to drive impact to patients, through targeted partnerships that strengthen healthcare systems in a sustainable way, at every stage of the patient journey. Takeda has positively impacted the lives of patients around the world through our Access to Medicines initiative. These efforts are led and managed from our GEM offices in Singapore.

Therapeutic Focus Areas

We are committed to bringing innovative medicines from across our chosen therapeutic areas of focus to transform patient lives in the 49 GEM countries and territories where a substantial number of people have little or no access to healthcare.

  • Oncology
  • Gastroenterology
  • Plasma-derived therapies
  • Rare diseases
  • Neuroscience

View All GEM Jobs


Key Locations

Our GEM BU serves patients in 49 countries and territories, with about 7,000 employees across 15 time zones, speaking more than 20 languages.

From our regional headquarters in Singapore, we lead and support the delivery of sustainable, profitable growth across our three key countries – Brazil, China and Russia – and three geographic areas – APAC (Asia Pacific), ICMEA (India, CIS, the Middle East and Africa) and SAM (South Cone, Andean, Mexico, Central America and the Caribbean). There are also eight manufacturing sites co-located within the GEM region. These are in Argentina, Brazil, China, India, Indonesia, Mexico, Russia and Singapore.

Map of the world with highlighted locations in Brazil, Russia, China, SAM, ICMEA, and Asia Pacific.
  • Brazil
  • Russia
  • China
  • SAM: South Cone, Andean and Mexico & CAC (Central America & Caribbean)
  • ICMEA: India, CIS, the Middle East, including Turkey, & Africa
  • Asia Pacific

Job Alerts

Would you like to receive relevant opportunities in your inbox as soon as they’re posted?


Sign up for Job Alerts

Sign up to receive the latest career opportunities directly to your inbox.

Interested In Select a job category from the list of options. Select a location from the list of options. Finally, click “Add” to create your job alert.

Are you interested in remote roles? Select One

By submitting your information, you acknowledge that you have read ourprivacy policyand consent to receive email communication from Takeda Pharmaceuticals.

Talent Network

Are you interested in company news, attending career events, and hearing more from Takeda?


By submitting your information, you acknowledge that you have read ourprivacy policyand consent to receive email communication from Takeda Pharmaceuticals.